Centene is trading 4.6% up at $69.69 in pre-market, driven by recent analyst upgrades and a strong Q1 2026 earnings beat. The stock is rebounding after a sharp selloff tied to its 2025 guidance withdrawal and ACA marketplace concerns.
- Truist Financial recently raised its price target from $71 to $78, reiterating a buy rating.
- The company reported $3.37 EPS for Q1 2026, significantly topping analysts' estimates of $2.23, and raised its 2026 earnings guidance.
- Investors are also responding to signs of stabilizing medical cost trends and effective management expense efforts.